Although the primary endpoint of this study was non-fatal myocardial infarction, non-fatal stroke or cardiovascular death, and the study was not powered to investigate differences in cancer outcomes, these findings support pre-clinical data on the potential role of IL1β inhibition for cancer control. The gene discussed is IL1B; the disease is cancer.